3 results

  • rystiggo

    (ROZANOLIXIZUMAB)
    UCB, Inc.
    RYSTIGGO is indicated for treating generalized myasthenia gravis (gMG) in adult patients who test positive for either anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibodies.

  • vyvgart

    (EFGARTIGIMOD ALFA)
    argenx US
    VYVGART is indicated for the treatment of generalized myasthenia gravis (gMG) in adult patients who test positive for anti-acetylcholine receptor (AChR) antibodies.

  • vyvgart hytrulo

    (efgartigimod alfa and hyaluronidase (human recombinant))
    argenx US
    VYVGART HYTRULO is indicated for the treatment of adult patients with generalized myasthenia gravis (gMG) who are anti-AChR antibody positive and for chronic inflammatory demyelinating polyneuropathy (CIDP).